http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Renata M. Martinez,Daniela T. Longhi-Balbinot,Ana C. Zarpelon,Larissa Staurengo-Ferrari,Marcela M. Baracat,Sandra R. Georgetti,Roge´rio C. Sassonia,Waldiceu A. Verri Jr.,Rubia Casagrande 대한약학회 2015 Archives of Pharmacal Research Vol.38 No.4
We have recently developed betalain-richbeetroot (Beta vulgaris) dye (betalain) to be used in foodproducts. Betalain (30–300 mg/kg) intraperitoneal (i.p.)treatment diminished carrageenan (100 lg/paw)-inducedpaw edema and neutrophil migration to the paw skin tissue. Betalain (100 mg/kg) treatment by subcutaneous or peroral routes also inhibited the carrageenan-induced pawedema. Importantly, the post-treatment with betalain(100 mg/kg, i.p.) significantly inhibited carrageenan- andcomplete Freund’s adjuvant (10 ll/paw)-induced pawedema. Betalain (100 mg/kg) also reduced carrageenan(500 lg/cavity)-induced recruitment of total leukocytes,including mononuclear cells and neutrophils, as well asincreasing vascular permeability in the peritoneal cavity. Furthermore, betalain significantly reduced carrageenaninducedsuperoxide anion, tumor necrosis factor-alpha(TNF-a) and interleukin (IL)-1b levels in the peritonealfluid, as well as augmenting IL-10 levels. Therefore, thiscompound presents prominent anti-inflammatory effect oncarrageenan-induced paw edema and peritonitis by reducingthe production of superoxide anion and the cytokinesTNF-a and IL-1b, in addition to increasing IL-10 levels. These results suggest that betalain shows therapeuticpotential that could be utilized in the treatment of inflammation-associated diseases.